Larissa A. Meyer, MD, MPH, FACOG, FACS

Peer-Reviewed Articles

1. Suidan RS, He W, Sun CC, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH, Meyer LA. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer 27(7):1350-1359, 2017. e-Pub 2017. PMID: 28574929.
2. Swanick CW, Eifel PJ, Huo J, Meyer LA, Smith GL. Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer. Gynecol Oncol 146(1):87-93, 2017. e-Pub 2017. PMID: 28506563.
3. Taylor JS, Rajan SS, Zhang N, Meyer LA , Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH. End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. J Clin Oncol 35(16):JCO2016702894, 2017. e-Pub 2017. PMID: 28388292.
4. Osborne EM, Klopp AH, Jhingran A, Meyer LA , Eifel PJ. Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy. Pract Radiat Oncol 7(3):173, 2017. e-Pub 2016.
5. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA . Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol 145(1):55-60, 2017. e-Pub 2017. PMID: 28131529.
6. Taylor JS, Marten CA, Munsell MF, Sun CC, Potts KA, Burzawa JK, Nick AM, Meyer LA, Myers K, Bodurka DC, Aloia TA, Levenback CF, Lairson DR, Schmeler KM. The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol 24(2):362-368, 2017. e-Pub 2016. PMID: 27573526.
7. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA , Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol 2(11):1427-1433, 2016. e-Pub 2016. PMID: 27442965.
8. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA , Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(28):3460-73, 2016. e-Pub 2016. PMID: 27502591.
9. Meyer LA , Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol 34(32):3854-3863. e-Pub 2016. PMID: 27601552.
10. Taylor JS, Marten CS, Potts KA, Cloutier LM, Cain KE, Fenton SL, Tatum TN, James DA, Myers KN, Hubbs CA, Burzawa JK, Vachhani S, Nick AM, Meyer LA , Graviss LS, Ware KM, Park AK, Aloia TA, Bodurka DC, Levenback CF, Schmeler KM. What Is the Real Rate of Surgical Site Infection?. J Oncol Pract 12(10):e878-e883. e-Pub 2016. PMID: 27460495.
11. Taylor JS, Zhang N, Meyer LA, Ramondetta LM, Bodurka DC, Rajan S, Giordano SH. Changing patterns of hospice and end of life care. J Clin Oncol 34, 2016.
12. Miralpeix E, Nick AM, Meyer LA, Cata J, Lasala J, Mena GE, Gottumukkala V, Iniesta-Donate M, Salvo G, Ramirez PT. A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programs. Gynecol Oncol 141(2):371-8, 2016. e-Pub 2016. PMID: 26906066.
13. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10(2):261-270, 2016. e-Pub 2015. PMID: 26245979.
14. Meyer LA, He W, Sun CC, Zhao H, Suidan RS, Lu KH, Giordano SH, Bodurka DC. Uptake and outcomes associated with neoadjuvant chemotherapy in the elderly: A population-based analysis. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer 141(1):169, 2016.
15. Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, Antrobus J, Huang J, Scott M, Wijk L, Acheson N, Ljungqvist O, Dowdy SC. Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations - Part II. Gynecol Oncol 140(2):323-32, 2016. PMID: 26757238.
16. Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, Antrobus J, Huang J, Scott M, Wijk L, Acheson N, Ljungqvist O, Dowdy SC. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations - Part I. Gynecol Oncol 140(2):313-22, 2016. PMID: 26603969.
17. Gockley AA, Rauh-Hain JA, Anders AM, Meyer LA, Clemmer J, Lu KH, Clark RM, Schorge JO, Del Carmen MG. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. Int J Gynecol Cancer 26(4):697-704, 2016. PMID: 26825834.
18. Rauh-Hain JA, Pepin KJ, Meyer LA, Clemmer JT, Lu KH, Rice LW, Uppal S, Schorge JO, Del Carmen MG. Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer. Obstet Gynecol 126(6):1198-206, 2015. e-Pub 2015. PMID: 26551187.
19. Rauh-Hain JA, Diver E, Meyer LA, Clemmer J, Lu KH, Del Carmen MG, Schorge JO. Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: Analysis of the National Cancer Database. Gynecol Oncol 139(1):77-83, 2015. PMID: 26325526.
20. Rauh-Hain JA, Starbuck KD, Meyer LA, Clemmer J, Schorge JO, Lu KH, Del Carmen MG. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A National Cancer Database analysis. Gynecol Oncol 139(1):84-89, 2015. PMID: 26307402.
21. Ramondetta LM, Meyer LA, Schmeler K, Sun CC. Avoidable Tragedies, Disparities in Healthcare Access Among Medically Underserved Women Diagnosed with Cervical Cancer. Gynecol Oncol 139(3):500-505. e-Pub 2015. PMID: 26498912.
22. Arms RG 3rd, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol 138(3):727-30, 2015. PMID: 26197762.
23. Kim YJ, Munsell MF, Park JC, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Williams JL, Bruera E, Ramondetta LM. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol 139(3):553-558, 2015. PMID: 26432043.
24. Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland C, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol, 2015. PMID: 26240233.
25. Meyer LA, Bohlke K, Powell MA, Fader AN, Franklin GE, Lee LJ, Matei D, Coallier L, Wright AA. Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. e-Pub 2015. PMID: 26150442.
26. Smith GL, Jiang J, Giordano SH, Meyer LA, Eifel PJ. Trends in the quality of treatment for patients with intact cervical cancer in the United States, 1999 through 2011. Int J Radiat Oncol Biol Phys 92(2):260-7, 2015. PMID: 25968823.
27. Hobeika M, Meyer LA. Massive lympohocele causing anorexia and deep-vein thrombosis after pelvic surgery. Surgery 157(3):601-2, 2015. e-Pub 2014. PMID: 25879113.
28. Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT. Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients. Gynecol Oncol 136(3):440-5, 2015. e-Pub 2015. PMID: 25647455.
29. Bishop AJ, Allen PK, Klopp AH, Meyer LA, Eifel PJ. Relationship Between Low Hemoglobin Levels and Outcomes after Treatment with Radiation or Chemoradiation in Patients with Cervical Cancer: Has the Impact of Anemia Been Overstated?. Int J Radiat Oncol Biol Phys 91(1):196-205, 2015. PMID: 25446609.
30. Jones N, Fleming N, Nick A, Munsell M, Rallapalli V, Westin S, Meyer LA, Schmeler K, Ramirez PT, Soliman P. Conversion from robotic surgery to laparotomy: A case-control study evaluating risk factors for conversion. Gynecol Oncol 134(2):238-242, 2014. e-Pub 2014. PMID: 24937481.
31. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer 24(4):713-717, 2014. PMID: 24651628.
32. Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol 209(1):24.e1-24.e12, 2013. e-Pub 2013. PMID: 23500454.
33. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107(10):1776-1782, 2012. e-Pub 2012. PMID: 23047548.
34. Wang LE, Ma H, Hale KS, Yin M, Meyer LA, Liu H, Li J, Lu KH, Hennessy BT, Li X, Spitz MR, Wei Q, Mills GB. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 138(3):377-385, 2012. e-Pub 2011. PMID: 22146979.
35. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121(2):358-363, 2011. e-Pub 2011. PMID: 21276604.
36. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, Lu KH. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 204(4):355.e1-357, 2011. e-Pub 2011. PMID: 21324431.
37. Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, Meyer L, Wu X, Liang D. Genetic variants in TGF-β pathway are associated with ovarian cancer risk. PLoS One 6(9):e25559, 2011. e-Pub 2011. PMID: 21984931.
38. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 70(23):9765-9776, 2010. e-Pub 2010. PMID: 21118967.
39. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28(22):3570-3576, 2010. e-Pub 2010. PMID: 20606085.
40. Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 115(5):945-952, 2010. PMID: 20410767.
41. Tung CS, Sun CC, Schlumbrecht MP, Meyer LA, Bodurka DC. Survival after intestinal perforation: can it be predicted?. Gynecol Oncol 115(3):349-353, 2009. e-Pub 2009. PMID: 19765809.
42. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 200(2):186.e1-188, 2009. PMID: 19185100.
43. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111(1):132-136, 2008. e-Pub 2008. PMID: 18684498.
44. Meyer LA, Ascher-Walsh CJ, Norman R, Idrissa A, Herbert H, Kimso O, Wilkinson J. Commonalities among women who experienced vesicovaginal fistulae as a result of obstetric trauma in Niger: results from a survey given at the National Hospital Fistula Center, Niamey, Niger. Am J Obstet Gynecol 197(1):e1-4, 2007. PMID: 17618772.
45. Frumovitz M, Singh DK,Meyer LA, Smith DH, Wertheim I, Resnik E, Bodurka D. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 95(3):463-468, 2004. PMID: 15581947.
46. Pothuri B, Meyer L, Gerardi M, Barakat RR, Chi DS. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol 95(1):193-195, 2004. PMID: 15385131.
47. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Dürst M, Pothuri B, Murty VV. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64(9):2994-2997, 2004. PMID: 15126331.

Invited Articles

1. Cohn DE, Ko E, Meyer LA , Wright JD, Temkin SM, Foote J, Jones NL, Havrilesky LJ. The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. Gynecol Oncol 145(1):185-191, 2017. e-Pub 2017. PMID: 28258763.
2. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 8(7):1159-67, 2008. PMID: 18588460.

Other Articles

1. Meyer L, Broaddus RR, Lu KH Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 16(1):14-22, 2009. PMID: 19078925.

Abstracts

1. Meyer LA , Shi Q, Iniesta M, Harris M, Sun C, Lasala J, Wang Q, Nick A, Lu K, Ramirez P. Comparison of patient reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Proceedings of the 2017 ASCO Annual Meeting, 2017.
2. Suidan R, He W, Sun C, Zhao H, Lu K, Giordano S, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Proceedings of the 2017 ASCO Annual Meeting, 2017.
3. Meyer LA , Li Yao, Rodriguez A, Nick A, Lasala J, Guzman A, Calhoun J, Iniesta M, Harris M, Earles T, Lu K, Ramirez P. A cost comparison of resource utilization before and after implementing an enhanced recover after surgery (ERAS) program-A significant impact on the ‘bottom line’. World Congress of Enhanced Recovery After Surgery 2017, 2017.
4. Salvo G, Meyer LA , Lasala J, Iniesta M, Sheth N, Munsell M, Rodriguez-Restrepo A, Corzo C, Lu K, Ramirez P. Implementation of an Enhanced Recovery After Surgery (ERAS) Program: The MD Anderson Cancer Center Experience. World Congress of Enhanced Receovery After Surgery 2017, 2017.
5. Dood R, Meyer L , Lasala J, Cata J, Mena G, Rodriguez A, Iniesta M, Sheth N, Salvo G, Lu K, Ramirez P. Return to intended oncologic therapy (RIOT) after surgery for gynecologic cancer in an enhanced recovery after surgery (ERAS) program. World Congress of Enhanced Recovery After Surgery 2017, 2017.
6. Lasala J, Mena G, Iniesta M, Rodriguez-Restrepo A, Meyer LA , Salvo G, Corzo X, Munsell M, Heir J, Ifeanyi I, Cata J, Lu K, Ramirez P. Impact of an enhanced recovery after surgery (ERAS) program on postoperative renal function. World Congress of Enhanced Recovery After Surgery 2017, 2017.
7. Rodriguez-Restrepo A, Iniesta M, Salvo G, Sheth N, Corzo C, Lasala J, Meyer LA , Munsell M, Lu K, Ramirez P. Compliance with an enhanced recovery after surgery (ERAS) program in gynecologic surgery: impact on length of stay and complications. World Congress of Enhanced Recovery After Surgery 2017, 2017.
8. Prescott LS, Taylor JS, Marten CA, Munsell MF, Myers K, Meyer LA , Ramirez PT, Levenback CF, Bodurka DC, Schmeler KM. Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology. Proceedings of the Society of Gynecologic Oncologists 48th Annual Meeting, 2017.
9. Suidan RS, Sun C, Cantor S, Mariani A, Soliman P, Westin S, Lu K, Giordano S, Meyer LA . A cost-utility analysis of sentinel lymph node mapping, selective lymphadenectomy, and routing lymphadenectomy in the management of low-risk endometrial carcinoma. Proceedings of the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, 2017.
10. Suidan RS, He W, Sun C, Zhao H, Smith G, Klopp A, Fleming N, Lu K, Giordano S, Meyer L . National Trends, Outcomes, and Costs of Radiation Therapy in the Management of Low- and High- Intermediate Risk Endometrial Carcinoma. Proceedings of the 2017 ASCO Quality Care Symposium, 2017.
11. Meyer L , Suidan R, He W, Sun CC, Zhao H, Westin S, Soliman P, Woodard T, Lu K, Giordano S. Endometrial hyperplasia and cancer in young women: A study of national patterns of care over time and pregnancy outcomes. 16th Biennial Meeting of the International Gynecologic Cancer Society, 2016.
12. Meyer LA , Suidan RS, He W, Sun CC, Zhao H, Westin SN, Fleming ND, Soliman PT, Lu KH, Giordano SH. National patterns of care for women of child-bearing age with endometrial hyperplasia and cancer. 16th Biennial Meeting of the International Gynecologic Cancer Society, 2016.
13. Taylor JS, Zhang N, Meyer LA, Ramondetta LM, Bodurka DC, Rajan S, Giordano SH. When more is less: End-of-life disparities among ovarian cancer patients. J Clin Oncol 34, 2016.
14. Suidan RS, He W, Sun CC, Soliman PT, Ramirez PT, Zhao H, Fleming ND, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index on surgical costs and morbidity for women with endometrial carcinoma/hyperplasia. J Clin Oncol 34, 2016.
15. Lasala JD, Nick AM, Ramirez PT, Meyer LA, Cain KE, Munsell MF, Iniesta MD, Ifeanyi IC, Singh J, Calderon TM, Kwater P, Tsai J, Vachhani S, Cata JP, Mena G. Decreased intraoperative opioid consumption following institution of enhanced recovery program in open gynecologic surgery. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016.
16. Taylor JS, Marten CA, Sun CCL, Bodurka DC, Potts K, Nick AM,Meyer, LA , Levenback CF, Lairson DR, Schmeler KM. The cost-effectiveness of the DISINFECT Initiative (Decreasing the Incidence of Surgical INFECTions) in gynecologic oncology. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016.
17. Cain KE, Lasala JD, Nick AM, Meyer, LA, Iniesta MD, Earles TW, Munsell MF, Ramirez PT. Decreased postoperative opioid consumption following implementation of enhanced recovery pathway after gynecologic surgery. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016.
18. Suidan RS, He W, Sun CCL, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH,Meyer, LA. Treatment patterns and outcomes for bowel obstruction in elderly ovarian cancer patients: A population-based analysis. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016.
19. Lasala JD, Ifeanyi IC, Singh J, Earles JW, Palmer LD, Harris M, Ramirez PT, Calderon TM, Nick AM, Meyer, LA, Jackson TA. Implementation of an enhanced recovery after gynecologic oncology surgery pathway: Improving compliance with key elements of preoperative care. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016.
20. Soliman PT, Garcia E, Lang K, Villanueva V, Westin SN, Fleming ND, Feeley T, Lu KH,Meyer, LA. Evaluation of resource utilization using time-derived activity-based costing results in more effective processes and cost reduction. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016.
21. Meyer LA, Nick AM, Iniesta MD, Cain KE, Earler TW, Lasala JD, Shi Q, Wang XS, Lu KH, Ramirez PT. Is recovery really "enhanced" through enhanced recovery programs? An analysis of patient-reported perioperative symptom burden before and after implementation of an enhanced recovery pathway for gynecologic surgery. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016.
22. Meyer LA, Cronin AM, Sun CC, Bookman MA, Burger RA, Cristea M, Griggs JJ, Levenback C, Mantia-Smaldone G, Matulonis UA, Niland J, O'Malley DM, Wright AA. Use of neoadjuvant chemotherapy in advanced ovarian cancer. J Clin Oncol 33(15), 2015.
23. Earles TW, Harris MG, Palmer LD, Meyer LA, Iniesta MD, Lasala JD, Cain KE, Washington LD, Ramirez PT, Nick AM. An Evaluation of an Enhanced Recovery Program Established for Patients Undergoing Open Gynecologic Surgery. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015.
24. Iniesta MD, Patrono MG, Nick AM, Washington LD, Ramos KE, Earles TW, Lasala JD, Ramirez PT, Meyer LA. Utility of Activity Logs in an Enhanced Recovery Pathway in Gynecologic Surgery. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015.
25. Lasala JD, Meyer LA, Nick AM, Ramirez P, Mena GE, Cata LP, Gottumukkala V, Kwater P, Hancher-Hodges S, Cain K, Harris M, Palmer L. Implementation of an Enhanced Recovery after Gynecologic Oncology Surgery Pathway: Improving Compliance with Key Elements of Preoperative Care. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015.
26. Lasala JD, Cain KE, Meyer LA, Ramirez P, Iniesta-Donate M, Mena GE, Cata JP, Earles T, Gottumukkala V, Kwater P, Hancher-Hodges S, Speer B, Munsell M, Singh J, Nick AM. Decreased Intra-Operative Opioid Consumption Following Enhanced Surgery Within Enhanced Recovery after Gynecologic Surgery. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015.
27. Zhang Y, Allen P, Meyer LA, Sun CC, Basen-Engquist KM, Lu KH, Klopp AH. Visceral adiposity associated with increased risk of death from ovarian cancer. Gynecol Oncol 137:118, 2015.
28. Meyer LA, He W, Zhao H, Sun CC, Wright A, Bodurka DC, Lu KH, Giordano SH. Patterns of care and survival in a matched case–control study of intraperitoneal chemotherapy in a national population-based cohort of elderly ovarian cancer patients. Gynecol Oncol 137:175-176, 2015.
29. Ramondetta LM, Kim YJ, Munsell MF, Park J, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Bruera E. Symptom burden in women with advanced or recurrent cervical cancer referred to a supportive care center. Gynecol Oncol 137:197, 2015.
30. Wainwright A, Brimmage B, Barratt MS, Robazetti S, Gomez MP, Ramondetta LM, Schmeler KM, Meyer LA. Structured patient reminder systems and HPV vaccine completion rates: A quality improvement initiative. Gynecol Oncol 137:150, 2015.
31. O'Malley DM, Niland J, Bookman MA, Burger RA, Cristea M, Griggs J, Mantia-Smaldone GM, Meyer LA, Sun CC, Wright A, Cohn DE. The use of NCCN guideline therapy in the first line/adjuvant setting in patients with ovarian cancer from 6 NCCN institutions. Gynecol Oncol 137:42, 2015.
32. Zhang H, Gounder M, Murthy R, Helgason T, Hong D, Benjamin R, Meyer LA, Zinner R, Meric-Bernstam F. Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer. Proceedings of the 13th International Congress on Targeted Anticancer Therapies (TAT 2015), 2015.
33. Meyer LA, Brimmage B, Gomez M, Hodgson S, Barratt M, Schmeler K, Ramondetta L, Sun CC. Parental Risk Perception and Decision Making Regarding Vaccination of their Eligible Children with the Human Papillomavirus Vaccine. Proceedings of the 36th Annual Meeting of the Society for Medical Decision Making, 2014.
34. Meyer LA, Brimmage B, Gomez MP, Hodgson S, Dalrymple JL, Gregg A, Barratt MS. Barriers to human papillomavirus (HPV) vaccination: perspectives of parents of vaccine-eligible children. Gynecol Oncol 133(Suppl 1):37, 2014.
35. Brimmage B, Gomez MP, Hodgson S, Barratt MS, Dalrymple JL, Gregg A, Meyer, LA. Forgotten appointments equals missed opportunities: Exploring the reasons for low HPV vaccine series completion rates. Gynecol Oncol 133(Suppl 1):188, 2014.
36. Smith JA, Mathew LM, Gaikwad AG, Faro JP, Meyer, LA, Dalrymple JL. In vitro and in vitro evaluation of active hexose correlated compound (AHCC) for the erradication of HPV. Gynecol Oncol 133(Suppl 1):189, 2014.
37. Meyer LA, He W, Zhao H, Sun CC, Buchholz T, Lu K, Giordano S. Patterns of care and overall survival in the Medicare ovarian cancer population. J Clin Oncol 32(5s), 2014.
38. Meyer L, Slomovitz B, Djordjevic B, Iglesias D, Westin S, Broaddus R, Munsell M, Wolf J, Gershenson D, Lu K. Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer. Gynecol Oncol 125(Suppl. 1):S163, 2012.
39. Meyer L, Schmeler K, Wallbillich J, Soliman P, Frumovitz M, Burke C, Bodurka D, Levenback C. Clinical practice guidelines decrease unnecessary Pap tests in survivors of gynecologic malignancies. Gynecol Oncol 120(Suppl 1):S30, 2011.
40. Huang M, Westin S, Sun C, Meyer L, Tung C, Urbauer D, Bodurka D. Menopausal symptoms and the use of hormone replacement therapy: The gynecologic cancer survivors’ perspective. Gynecol Oncol 120(Suppl 1):S82, 2011.
41. Huang M, Djordjevic B, Urbauer D, Westin SN, Sun CC, Burzawa JK, Meyer L, Bodurka DC, Broaddus R, Lu KH. Molecular analysis of endometrial pathogenesis in Lynch Syndrome. J Clin Oncol 29, 2011.
42. Meyer LA, Slomovitz BM, Djordjevic B, Galbincea JM, Johnston TA, Munsell M, Burzawa JK, Huang M, Broaddus R, Iglesias DA, Coleman RL, Gershenson DM, Burke TW, Wolf J, Lu KH. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. J Clin Oncol 29, 2011.
43. Meyer LA, Liang D, Lin J, Ye Y, Huang M, Pu X, Lu K, Wu X. Genetic Variants in the mammalian target of rapamycin (mTOR) pathway as predictors of clinical response and survival in women with ovarian cancer. Gynecol Oncol 120(Suppl 1):S23, 2010.
44. Burzawa J, Schmandt R, Bowser J, Zhang Q, Huang M, Meyer L, Westin S, Gershenson D, Lu K. Preclinical evidence for exercise and pharmacologic exercise mimetics in the treatment of endometrial cancer. Gynecol Oncol 116(3 Supp 1):S80, 2010.
45. Westin SN, Sun CC, Schlumbrecht MP, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Soliman PT, Lu KH, Bodurka DC. Persistent obesity among endometrial cancer survivors: A teachable moment?. Gynecol Oncol 116:S81, 2010.
46. Huang M, Burzawa J, Djordjevic B, McCampbell A, Boyd-Togers S, Meyer L, Westin S, Broaddus R, Lu K. Preinvasive disease in patients with Lynch syndrome-associated endometrial cancer. Gynecol Oncol 116(3 Supp 1):S97, 2010.
47. Burke CC, Meyer LA, Daniels MS, Schmeler KM, Garcia EA, Zook SU, Zalun G, Sam AV, Rothe ER, Anderson ME, Gershenson DM, Lu KH. Identification of women with ovarian cancer at risk for BRCA 1/2 mutations: Initial Results from a quality improvement initiative. Gynecol Oncol 112(2, Suppl. 1):S20, 2009.
48. Burzawa JK, Schmeler KM, Soliman PT, Lacour RA, Meyer LA, Bevers MW, Frumovitz MM, Pustilnik T, Brown J, Anderson ML, Ramondetta LM, Tortolero-Luna G, Gershenson DM, Lu KH. Prospective, population-based evaluation of insulin resistance, polycystic ovary syndrome and metabolic syndrome in a cohort of patients with endometrial cancer. Gynecol Oncol 112(2, Suppl. 1):S85, 2009.
49. Meyer LA, Anderson ME, Lacour RA, Westin SN, Burzawa JK, Urbauer DL, Daniels MS, Burke CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1 and BRCA 2 mutations: A trend over time. Gynecol Oncol 112(2, Suppl. 1):S96, 2009.
50. Liang D, Meyer LA, Lin J, Xia P, Ye Y, Wu L, Lu K, Wu X. Genetic Variants in microRNA processing pathway genes and ovarian cancer risk [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver CO Philadelphia (PA): AACR, 2009.
51. Westin SN, Sun CC, Lacour RA, Meyer, LA, Tung CS, Urbauer DL, Frumovitz MM, Lu KH, Gershenson DM, Bodurka DC. Survivors of Gynecologic Malignancies: Impact of treatment on health and well- being. J Clin Oncol 26(7s, Suppl), 2008.
52. Zhang Q, Celestino J, Shen Q, Milam M, Westin S, Lacour R, Meyer L, Shipley G, Davies P, Lu K.. Estrogen- induced cell proliferation and cell- cycle signaling in obese rat endometrium, 2008.
53. Lacour RA, White KG, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik T, Urbauer DL, Sun CC, Bodurka DC, Gershenson DM, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 108(Suppl.1):S59, 2008.
54. Lacour RA, Daniels MS, Westin SN, ,Meyer, LA Choubey V, Blank SV, MacDonald HR, Roman L, Estes JM, Barnes M, Teoh D, Powell B, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-ovarian cancer?. Gynecol Oncol 108(Suppl. 1):S108-109, 2008.
55. Westin SN, Lu KH, Milam MR, Lacour, RA, Meyer, LA, Urbauer, DL, Bodurka DC, Broaddus, RR. Adenocarcinoma of the lower uterine segment: A distinct clinical entity associated with Lynch Syndrome. Gynecol Oncol 108(Suppl. 1):S64-65, 2008.
56. Westin SN, Lu KH, Lacour RA, Meyer LA, Xie S, Urbauer DL, Broaddus RR. GRP78 has unique expression in normal endometrium and endometrial carcinoma. Gynecol Oncol 108(Suppl. 1):S74, 2008.
57. Meyer LA, Westin SN, Lacour RA, Urbauer DL, Schmeler KM, Daniels MS, Sun CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1/2: Missed opportunities. J Clin Oncol 26(7s, Suppl), 2008.
58. Lacour, RA, Westin, SN,Meyer, LA , Soliman, PT, Keeler, ER, Boyd-Rogers, SG, Urbauer, DL, Broaddus, RR, Loose, DS, Lu, KH. Alterations in estrogen-associated proliferation markers in histologically-normal endometrium of obese women. J Clin Oncol 26(May 20- suppl), 2008.
59. Meyer L, Ascher-Walsh CJ, Norman R, Idrissa A, Herbert H, Kimso O, Wilkinson J. Commonalities among women who experienced vesicovaginal fistulae as a result of obstetric trauma in Niger: results from a survey given at the National Hospital Fistula Center, Niamey, Niger. Am J Obstet Gynecol 197(1):90.e1-4, 2007. PMID: 17618772.
60. Meyer L, Pothuri B. Decompressive percutaneous gastrostomy tube use in gynecologic malignancies. Curr Treat Options Oncol 7(2):111-20, 2006. PMID: 16455022.
61. Ascher-Walsh CJ, Meyer L, Norman R, Wilkinson JP. Access to healthcare, patient comprehension during preoperative counseling, and understanding of future plans of women undergoing surgery for repair of a vesico-vaginal fistula in western Niger: A report from a survey given at the National Hospital Fistula Center, Niamey, Niger. Int Urogynecol J 17(Suppl. 3):S411-412, 2006.
62. Pothuri B, Meyer L, Herzog T, Cohen C, Arons R.. Radiation is a risk factor for colon cancer development in patients with primary cervical cancer. Gynecol Oncol 101(S119), 2006.
63. Awtrey C, Meyer L, Kauff N. Levine D, Barakat R. Primary peritoneal cancer (PPC) following bilateral salpingo-oophorectomy (BSO). Gynecol Oncol 96:934, 2005.
64. Graham G, Meyer L, Perez-Delboy A, Simpson L. The yield of congenital heart disease by indication for fetal echocardiogram. Journal of Ultrasound in Medicine 23(S101), 2004.

Book Chapters

1. Jhingran A, Meyer LA. Malignant Diseases of the Cervix - Microinvasive and Invasive Carcinoma: Diagnosis and Management. In: Comprehensive Gynecology. 7. Elsevier: Philadelphia, PA, 666-685, 2021.
2. Westin SN, Meyer LA, Coleman RL. Ovarian Cancer. In: Targeted Therapy in Translational Cancer Research. Wiley Blackwell, 240-254, 2015.
3. Meyer L, Pothuri B. Early Cervical Cancer. In: Gynecologic Tumor Board: Clinical Cases in Diagnosis and Management of Cancer of the Female Reproductive System. Jones and Bartlett Publishers: Sudury, MA, 145-156, 2009.

Letters to the Editor

1. Meyer LA , Wright AA. Reply to M.S. Copur et al. J Clin Oncol 35: 803, 2017.